@article{96ab42c0d582409b9a6fc710b0b194af,
title = "Deep learning based on standard H&E images of primary melanoma tumors identifies patients at risk for visceral recurrence and death",
abstract = "Purpose: Biomarkers for disease-specific survival (DSS) in early-stage melanoma are needed to select patients for adjuvant immunotherapy and accelerate clinical trial design. We present a pathology-based computational method using a deep neural network architecture for DSS prediction. Experimental Design: The model was trained on 108 patients from four institutions and tested on 104 patients from Yale School of Medicine (YSM, New Haven, CT). A receiver operating characteristic (ROC) curve was generated on the basis of vote aggregation of individual image sequences, an optimized cutoff was selected, and the computational model was tested on a third independent population of 51 patients from Geisinger Health Systems (GHS). Results: Area under the curve (AUC) in the YSM patients was 0.905 (P < 0.0001). AUC in the GHS patients was 0.880 (P < 0.0001). Using the cutoff selected in the YSM cohort, the computational model predicted DSS in the GHS cohort based on Kaplan-Meier (KM) analysis (P < 0.0001). Conclusions: The novel method presented is applicable to digital images, obviating the need for sample shipment and manipulation and representing a practical advance over current genetic and IHC-based methods.",
author = "Kulkarni, {Prathamesh M.} and Robinson, {Eric J.} and Pradhan, {Jaya Sarin} and Gartrell-Corrado, {Robyn D.} and Rohr, {Bethany R.} and Trager, {Megan H.} and Geskin, {Larisa J.} and Kluger, {Harriet M.} and Wong, {Pok Fai} and Balazs Acs and Rizk, {Emanuelle M.} and Chen Yang and Manas Mondal and Moore, {Michael R.} and Iman Osman and Robert Phelps and Horst, {Basil A.} and Chen, {Zhe S.} and Tammie Ferringer and Rimm, {David L.} and Jing Wang and Saenger, {Yvonne M.}",
note = "Funding Information: This publication was supported by the NIH through grant numbers R01FD006108 (to Y.M. Saenger), UH2CA218149 (to Y.M. Saenger), and KL2TR001874 (to R.D. Gartrell-Corrado). This project also received funding from the Melanoma Research Alliance (to Y.M. Saenger), Columbia University's Irving Institute for Clinical and Translational Research (to Y.M. Saenger), and Swim Across America (to R.D. Gartrell-Corrado). This work was supported by funds from Navigate BioPharma (Novartis subsidiary), Yale SPORE in Lung Cancer (P50CA196530) and Yale Cancer Center (P30CA016359; to D.L. Rimm). The funding sources had no role in study design; collection, analysis, and interpretation of data; preparation of the manuscript; or the decision to submit for publication. Funding Information: E.M. Rizk reports receiving other remuneration from NanoString. D.L. Rimm is an employee/paid consultant for Konica Minolta, Ventana, and NanoString, and reports receiving commercial research grants from Lilly and NextCure. J. Wang is listed as a co-inventor on a provisional patent application on “Systems and Methods for Tumor Characterization” that is owned by NYU Langone Health and in negotiation to be licensed to Wasaba Diagnostics. Y.M. Saenger reports receiving other commercial research support from Amgen, and holds ownership interest (including patents) in Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research Inc.. All rights reserved.",
year = "2020",
month = mar,
day = "1",
doi = "10.1158/1078-0432.CCR-19-1495",
language = "English (US)",
volume = "26",
pages = "1126--1134",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",
}